by Mark Boslet
Posted on: April 12, 2013 by Mark BosletNo Comments »
Eyevensys said it received an equity investment from the Boehringer Ingelheim Venture Fund. Further details were not available. The company raised about $2.1 million in its first round of funding in January 2012. It said early investors – Innobio, managed by CDC Entreprises; Inserm Transfert Initiative; and CapDecisif Management – plan to participate in the second round.
by asormani
Posted on: December 3, 2012 by asormaniNo Comments »
ArmaGen Technologies has closed a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics. The lead investor is Boehringer Ingelheim Venture Fund, joined by Shire plc, Takeda Ventures, Inc., and Mitsui & Co. Global Investment, Inc.
Yahoo’s $1.1 billion planned purchase of blogging site Tumblr is the largest exit of a pre-public venture-backed New York-based company
Author : mboslet
It’s that time of the year when every VC (or, well, most VCs) secretly pulls up Forbes’ Midas list and,
Author : mahendra
MassChallenge said it selected 128 startups for its 2013 MassChallenge Accelerator Program. The companies come from eighteen states and 11
Author : mboslet
Over a 10-year period ending in 2011, Harvard Business School professor Noam Wasserman researched roughly 10,000 founders, finding that by
Author : connieloizos
Venture-backed IPO activity has been sluggish so far this year, but there are signs this could change. Two recent issues,
Author : mboslet
Welcome! Join the peHUB community to make connections, share your opinion, and follow your favorite authors. It's quick and easy.
Click here to get started!
